Outlook Therapeutics reports Q3 net loss $20.7M; reiterates Aug 29 PDUFA for ONS-5010

Outlook Therapeutics, Inc.

2023-Q3 EPS reported -$0.19

Net loss attributable to common stockholders of $20.7M ($0.08/share) vs $17.5M in prior-year quarter.
Cash and cash equivalents of $33.7M expected to fund operations through potential BLA approval in Q3 2023.
FDA PDUFA goal date of August 29, 2023 for ONS-5010 (ophthalmic bevacizumab) for wet AMD.
Pre-launch activities ongoing with AmerisourceBergen distribution partnership for U.S. launch.
MAA decision from EMA CHMP for ONS-5010 in EU expected in first half of 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Outlook Therapeutics, Inc. reported financial results for third fiscal quarter ended June 30, 2023.

Period: third fiscal quarter ended June 30, 2023
Result: reported results

Exact text from the filing

On August 14, 2023, Outlook Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for its third fiscal quarter ended June 30, 2023.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

Outlook Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-091353

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.